Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Roche to buy CAR-T firm Poseida Therapeutics

by Sarah Braner
December 8, 2024 | A version of this story appeared in Volume 102, Issue 38

 

Roche has agreed to acquire Poseida Therapeutics, a chimeric antigen receptor T-cell (CAR-T) therapy company based in San Diego, for about $1.5 billion. Roche and Poseida already have a partnership to develop therapies for hematologic cancers; the purchase will add Poseida’s solid- tumor and autoimmune programs and genetic engineering platform. Poseida has three CAR-T candidates in Phase 1 trials. In partnership with Roche, it has one candidate for B-cell malignancies and one for multiple myeloma; separate from Roche, it has a candidate for solid tumors in breast, ovarian, renal, colorectal, lung, and pancreatic cancers.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.